Header Logo

Johnny

Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Windyga J, Apte S, Frei-Jones M, Fujii T, Lyu CJ, Villarreal Martinez L, Sathar J, Stasyshyn O, Tran H, Zozulya N, Brown Frandsen R, Neergaard JS, Thaung Zaw JJ, Mahlangu J. Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study. Eur J Haematol. 2024 Jul 19. PMID: 39030946.
      Citations:    Fields:    
    2. Z?lfikar B, Mahlangu J, Nekkal SM, Ross C, Uaprasert N, Windyga J, Ettingshausen CE, Ploder B, Lelli A, Gazda HT. Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors. TH Open. 2024 Jul; 8(3):e273-e282. PMID: 38983688; PMCID: PMC11230701.
      Citations:    
    3. Doxzen KW, Adair JE, Fonseca Bazzo YM, Bukini D, Cornetta K, Dalal V, Guerino-Cunha RL, Hongeng S, Jotwani G, Kityo-Mutuluuza C, Lakshmanan K, Mahlangu J, Makani J, Mathews V, Ozelo MC, Rangarajan S, Scholefield J, Batista Silva J?nior J, McCune JM. The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024 May 08; 16(746):eadn1902. PMID: 38718130.
      Citations:    Fields:    Translation:Humans
    4. Young G, Pipe SW, Kenet G, Oldenburg J, Safavi M, Czirok T, Nissen F, Mahlangu J. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review. Res Pract Thromb Haemost. 2024 May; 8(4):102415. PMID: 38812987; PMCID: PMC11135026.
      Citations:    
    5. Madan B, Ozelo MC, Raheja P, Symington E, Quon DV, Leavitt AD, Pipe SW, Lowe G, Kenet G, Reding MT, Mason J, Wang M, von Drygalski A, Klamroth R, Shapiro S, Chambost H, Dunn AL, Oldenburg J, Chou SC, Peyvandi F, Millar CM, Osmond D, Yu H, Dashiell-Aje E, Robinson TM, Mahlangu J. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893. PMID: 38614387.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    6. Jim?nez-Yuste V, Oldenburg J, Tzeng E, Lim E, Sanabria F, Mahlangu J. Emicizumab is efficacious in people with hemophilia A with comorbidities aged =50 years: analysis of 4 phase III trials. Res Pract Thromb Haemost. 2024 Mar; 8(3):102405. PMID: 38783987; PMCID: PMC11112372.
      Citations:    
    7. Mahlangu J, Diop S, Lavin M. Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85. PMID: 38462793.
      Citations:    Fields:    Translation:Humans
    8. Mahlangu J, Jim?nez-Yuste V, Ventriglia G, Niggli M, Barlera S, Hermans C, Lehle M, Chowdary P, Jew L, Windyga J, Frenzel L, Schmitt C, Castaman G, Pipe SW. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Res Pract Thromb Haemost. 2024 Feb; 8(2):102364. PMID: 38559572; PMCID: PMC10978536.
      Citations:    
    9. Miesbach W, Carcao M, Mahlangu J, Dargaud Y, Jimenez-Yuste V, Hermans C. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266. PMID: 38317441.
      Citations:    Fields:    Translation:Humans
    10. Miesbach W, Konkle B, Chowdary P, Kaczmarek R, Leebeek F, Mahlangu J, Makris M, Pipe SW, Srivastava A, Voorberg J, Pierce GF, Peyvandi F. Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024 May; 22(5):1510-1515. PMID: 38242208.
      Citations:    Fields:    Translation:Humans
    11. Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jim?nez-Yuste V, Shima M, N?grier C, Schmitt C. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost. 2024 Jan; 8(1):102306. PMID: 38282901; PMCID: PMC10818085.
      Citations:    
    12. Lentz SR, Chowdary P, Gil L, Lopez-Jaime FJ, Mahlangu J, Matytsina I, Nielsen AL, Windyga J. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000. PMID: 38142846.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Thachil J, Connors JM, Mahlangu J, Sholzberg M. "Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets": Reply. J Thromb Haemost. 2023 10; 21(10):2980-2981. PMID: 37739593.
      Citations:    Fields:    
    14. O'Mahony B, Dunn AL, Leavitt AD, Peyvandi F, Ozelo MC, Mahlangu J, Peerlinck K, Wang JD, Lowe GC, Tan CW, Giermasz A, Tran H, Khoo TL, Cockrell E, Pepperell D, Chambost H, L?pez Fern?ndez MF, Kazmi R, Majerus E, Skinner MW, Klamroth R, Quinn J, Yu H, Wong WY, Robinson TM, Pipe SW. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462. PMID: 37678546.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    15. Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jim?nez-Yuste V, explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794. PMID: 37646676.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    16. Konkle BA, Oldenburg J, Pasi J, Kulkarni R, Nolan B, Mahlangu J, Young G, Brown SA, Pabinger I, Shapiro A, N?grier C, Blanchette V, Ragni MV, Dumont J, Lethagen S. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults. Res Pract Thromb Haemost. 2023 Aug; 7(6):102180. PMID: 37753224; PMCID: PMC10518483.
      Citations: 1     
    17. Cornetta K, Kay S, Urio F, Minja IK, Mbugi E, Mgaya J, Mselle T, Nkya S, Alimohamed MZ, Ndaki K, Bonamino M, Koya RC, Shah LD, Mahlangu J, Drago D, Rangarajan S, Jayandharan GR. Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther. 2023 09 06; 31(9):2561-2565. PMID: 37595584; PMCID: PMC10492022.
      Citations:    Fields:    Translation:Humans
    18. Shapiro AD, Kulkarni R, Ragni MV, Chambost H, Mahlangu J, Oldenburg J, Nolan B, Ozelo MC, Foster MC, Willemze A, Barnowski C, Jain N, Winding B, Dumont J, Lethagen S, Barnes C, Pasi KJ. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057. PMID: 36848635; PMCID: PMC10331408.
      Citations: 1     Fields:    Translation:Humans
    19. Tigu AB, Hotea I, Drula R, Zimta AA, Dirzu N, Santa M, Constantinescu C, Dima D, Bergthorsson JT, Greiff V, Gulei D, Coriu D, Serban M, Mahlangu J, Tomuleasa C. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796. PMID: 37317065; PMCID: PMC10315746.
      Citations: 2     Fields:    Translation:Humans
    20. Kenet G, Moulton T, Wicklund BM, Ahuja SP, Escobar M, Mahlangu J. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials. J Blood Med. 2023; 14:379-388. PMID: 37309365; PMCID: PMC10257928.
      Citations:    
    21. Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, Mahlangu J, Kempton CL, Kessler CM, Kruse-Jarres R. Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]. Res Pract Thromb Haemost. 2023 May; 7(4):100191. PMID: 37538504; PMCID: PMC10394545.
      Citations:    
    22. Thachil J, Connors JM, Mahlangu J, Sholzberg M. Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740. PMID: 36972786.
      Citations: 2     Fields:    Translation:Humans
    23. Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DV, Symington E, Leavitt AD, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele KM, Reddy DB, Henshaw J, Robinson TM, Wong WY, Pipe SW, GENEr8-1 Trial Group. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705. PMID: 36812433.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    24. Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, Mahlangu J, Kempton CL, Kessler CM, Kruse-Jarres R. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. Res Pract Thromb Haemost. 2023 Feb; 7(2):100077. PMID: 36908770; PMCID: PMC9992752.
      Citations: 1     
    25. N?grier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jim?nez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177. PMID: 36716761.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    26. Mahlangu J, Luis Lamas J, Cristobal Morales J, Malan DR, Teeter J, Charnigo RJ, Hwang E, Arkin S. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248. PMID: 36220152; PMCID: PMC10092220.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    27. Mankgele M, Variava E, Moloantoa T, Otwombe K, Hlongwane K, Disenyane D, Bida M, Chikwati R, Snyman T, Martinson N, Mahlangu J. Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis. J Clin Pathol. 2023 Aug; 76(8):555-560. PMID: 36137739.
      Citations: 1     Fields:    Translation:Humans
    28. Callaghan MU, Asikanius E, Lehle M, Oldenburg J, Mahlangu J, Uguen M, Chebon S, Kruse-Jarres R, Jim?nez-Yuste V, Shima M, Trask P, Kempton CL, Kessler CM, Levy GG, Peyvandi F. Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3. Res Pract Thromb Haemost. 2022 Aug; 6(6):e12782. PMID: 36171959; PMCID: PMC9468791.
      Citations: 3     
    29. Mahlangu JN, Lamas JL, Morales JC, Malan DR, ?alek SZ, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P, Arkin S. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239. PMID: 35999026; PMCID: PMC10286764.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    30. Chowdary P, Holmstr?m M, Mahlangu JN, Ozelo MC, Pabinger I, Pasi KJ, Ragni MV, Shapiro A, Barnowski C, Lethagen S. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies. Res Pract Thromb Haemost. 2022 Jul; 6(5):e12760. PMID: 35910942; PMCID: PMC9326287.
      Citations: 2     
    31. Escobar MA, Beijlevelt M, Loney A, Mahlangu J, Nanayakkara L, Neme D, Pasta G, Toulon P, Tran H. World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia. 2022 09; 28(5):S129-S131. PMID: 35811115.
      Citations: 1     Fields:    Translation:Humans
    32. Mahlangu J, Bassa F, Bassingthwaighte M, Cruickshank AL, Du Plessis J, Goga Y, Joubert J, Louw V, Mahlachana N, Mathew R, Neethling B, Potgieter J, Rapiti N, Rayner B, Reynders D, Sutton C, Van Zyl A. Prophylaxis is the new standard of care in patients with haemophilia. S Afr Med J. 2022 05 31; 112(6):405-408. PMID: 36217868.
      Citations:    Fields:    Translation:Humans
    33. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110. PMID: 35521723.
      Citations: 14     Fields:    Translation:Humans
    34. Reiss UM, Mahlangu J, Ohmori T, Ozelo MC, Srivastava A, Zhang L. Haemophilia gene therapy-Update on new country initiatives. Haemophilia. 2022 May; 28 Suppl 4:61-67. PMID: 35521726.
      Citations: 4     Fields:    Translation:HumansCells
    35. Rees DC, Kilinc Y, Unal S, Dampier C, Pace BS, Kaya B, Trompeter S, Odame I, Mahlangu J, Unal S, Brent J, Grosse R, Fuh BR, Inusa BPD, Koren A, Leblebisatan G, Levin C, McNamara E, Meiser K, Hom D, Oliver SJ. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652. PMID: 35226723.
      Citations: 9     Fields:    Translation:Humans
    36. Swan D, Mahlangu J, Thachil J. Non-factor therapies for bleeding disorders: A primer for the general haematologist. EJHaem. 2022 Aug; 3(3):584-595. PMID: 36051064; PMCID: PMC9422036.
      Citations: 2     
    37. Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27. PMID: 35475308.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    38. Cornetta K, Bonamino M, Mahlangu J, Mingozzi F, Rangarajan S, Rao J. Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India. Mol Ther. 2022 Jun 01; 30(6):2122-2129. PMID: 35390542.
      Citations: 11     Fields:    
    39. Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B, GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025. PMID: 35294811.
      Citations: 65     Fields:    Translation:HumansCellsCTClinical Trials
    40. Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, Hardesty B, Shima M, Pollock T, Slev P, Oldenburg J, Ozelo MC, Stieltjes N, Castet SM, Mahlangu J, Peyvandi F, Kazmi R, Schved JF, Leavitt AD, Callaghan M, Pan-Petesch B, Quon DV, Andrews J, Trinh A, Li M, Wong WY. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr; 33(7-8):432-441. PMID: 35156839; PMCID: PMC9063149.
      Citations: 22     Fields:    Translation:HumansCells
    41. Mahlangu J, Abdul Karim F, Stasyshyn O, Korczowski B, Salazar B, Lucas S, Suen A, Goldstein B, Chung T, Pabinger I. Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study. Res Pract Thromb Haemost. 2022 Feb; 6(2):e12665. PMID: 35224416; PMCID: PMC8844480.
      Citations: 2     
    42. Kenet G, Chen YC, Lowe G, Percy C, Tran H, von Drygalski A, Trossaërt M, Reding M, Oldenburg J, Mingot-Castellano ME, Park YS, Peyvandi F, Ozelo MC, Mahlangu J, Quinn J, Huang M, Reddy DB, Kim B. Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. J Clin Med. 2021 Dec 18; 10(24). PMID: 34945255; PMCID: PMC8705574.
      Citations: 4     
    43. Nalado A, Waziri B, Olorunfemi G, Mahlangu J, Paget G, Duarte R, Naicker S. A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775. PMID: 35283988; PMCID: PMC8889839.
      Citations:    Fields:    Translation:Humans
    44. Constantinescu C, Jitaru C, Pasca S, Dima D, Dirzu N, Coriu D, Zdziarska J, Ghiaur G, Mahlangu J, Tomuleasa C. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022 05; 53:100907. PMID: 34776294.
      Citations: 4     Fields:    Translation:Humans
    45. Escobar M, Castaman G, Boix SB, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha IH, Négrier C, Quon D, Recht M, Schved JF, Shapiro AD, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska KV, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Macie C, Wilkinson TA, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931. PMID: 34636112.
      Citations: 6     Fields:    Translation:Humans
    46. O'Donovan M, Quinn E, Johnston K, Singleton E, Benson J, O'Mahony B, Noone D, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM, Mahlangu J. Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. Res Pract Thromb Haemost. 2021 Oct; 5(7):e12602. PMID: 34667923; PMCID: PMC8505226.
      Citations: 3     
    47. Parnes A, Mahlangu JN, Pipe SW, Paz-Priel I, Lehle M, Trask PC, Jiménez-Yuste V. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775. PMID: 34623725.
      Citations: 6     Fields:    Translation:Humans
    48. Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920. PMID: 34614267.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    49. Mahlangu J. An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138. PMID: 34404300.
      Citations: 2     Fields:    Translation:Humans
    50. Mahlangu J, Levy H, Kosinova MV, Khachatryan H, Korczowski B, Makhaldiani L, Iosava G, Lee M, Del Greco F. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. Res Pract Thromb Haemost. 2021 Aug; 5(6):e12576. PMID: 34430790; PMCID: PMC8371347.
      Citations: 6     
    51. van Galen KPM, d'Oiron R, James P, Abdul-Kadir R, Kouides PA, Kulkarni R, Mahlangu JN, Othman M, Peyvandi F, Rotellini D, Winikoff R, Sidonio RF. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887. PMID: 34327828; PMCID: PMC8361713.
      Citations: 24     Fields:    Translation:Humans
    52. Skinner MW, Négrier C, Paz-Priel I, Chebon S, Jiménez-Yuste V, Callaghan MU, Lehle M, Niggli M, Mahlangu J, Shapiro A, Shima M, Campinha-Bacote A, Levy GG, Oldenburg J, von Mackensen S, Pipe SW. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865. PMID: 34171159; PMCID: PMC8518882.
      Citations: 8     Fields:    Translation:Humans
    53. Mahlangu J, Levy H, Lee M, Del Greco F. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580. PMID: 33960073; PMCID: PMC8359950.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    54. Mahlangu JN. Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management. Front Med (Lausanne). 2021; 8:670526. PMID: 34026796; PMCID: PMC8131856.
      Citations: 8     
    55. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242. PMID: 33512413; PMCID: PMC8065240.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    56. Oldenburg J, Tran H, Peyvandi F, Núñez R, Trask P, Chebon S, Mahlangu JN, Lehle M, Jiménez-Yuste V, von Mackensen S. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407. PMID: 33576546.
      Citations: 6     Fields:    Translation:Humans
    57. Kempton C, Trask P, Parnes A, Niggli M, Campinha-Bacote A, U Callaghan M, O'Connell N, Paz-Priel I, Mahlangu JN. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228. PMID: 33506955; PMCID: PMC8048849.
      Citations: 9     Fields:    Translation:Humans
    58. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640. PMID: 33460559.
      Citations: 43     Fields:    Translation:Humans
    59. Peyvandi F, Mahlangu JN, Pipe SW, Hay CRM, Pierce GF, Kuebler P, Kruse-Jarres R, Shima M. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41. PMID: 33331041; PMCID: PMC7756327.
      Citations: 6     Fields:    Translation:Humans
    60. Pipe SW, Kruse-Jarres R, Mahlangu JN, Pierce GF, Peyvandi F, Kuebler P, De Ford C, Sanabria F, Ko RH, Chang T, Hay CRM. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021 01; 19 Suppl 1:21-31. PMID: 33331042; PMCID: PMC7756842.
      Citations: 3     Fields:    Translation:Humans
    61. Chetty T, Bouwer N, Wan YO, Mahlangu J. Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting. J Clin Pathol. 2022 Feb; 75(2):117-120. PMID: 33328180.
      Citations:    Fields:    Translation:Humans
    62. Konkle B, Pierce G, Coffin D, Naccache M, Clark RC, George L, Iorio A, O'Mahony B, Pipe S, Skinner M, Watson C, Peyvandi F, Mahlangu J, ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 11; 18(11):3074-3077. PMID: 33463024; PMCID: PMC7756325.
      Citations: 7     Fields:    Translation:Humans
    63. Mancuso ME, Mahlangu J, Sidonio R, Trask P, Uguen M, Chang T, Shima M, Young G, Oldenburg J, von Mackensen S. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018. PMID: 33084175; PMCID: PMC7821108.
      Citations: 3     Fields:    Translation:Humans
    64. Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, Paget G, Mahlangu J, Duarte R, George J, Naicker S. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020 09 29; 21(1):415. PMID: 32993549; PMCID: PMC7523312.
      Citations: 6     Fields:    Translation:Humans
    65. Oldenburg J, Shima M, Kruse-Jarres R, Santagostino E, Mahlangu J, Lehle M, Selak Bienz N, Chebon S, Asikanius E, Trask P, Mancuso ME, Jiménez-Yuste V, von Mackensen S, Levy GG. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474. PMID: 32776489.
      Citations: 4     Fields:    Translation:Humans
    66. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinás A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF, WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug; 26 Suppl 6:1-158. PMID: 32744769.
      Citations: 440     Fields:    Translation:Humans
    67. Spadarella G, Di Minno A, Brunetti-Pierri N, Mahlangu J, Di Minno G. The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021 03; 46:100737. PMID: 32739122.
      Citations: 4     Fields:    Translation:HumansAnimals
    68. Pasi KJ, Fischer K, Ragni M, Kulkarni R, Ozelo MC, Mahlangu J, Shapiro A, P'Ng S, Chambost H, Nolan B, Bennett C, Matsushita T, Winding B, Fruebis J, Yuan H, Rudin D, Oldenburg J. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271. PMID: 32497409.
      Citations: 16     Fields:    Translation:Humans
    69. Mahlangu JN, Blanchette V, Klamroth R. Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27. PMID: 32469108.
      Citations: 2     Fields:    Translation:Humans
    70. Konkle BA, Coffin D, Pierce GF, Clark C, George L, Iorio A, Mahlangu J, Naccache M, O'Mahony B, Peyvandi F, Pipe S, Quartel A, Sawyer EK, Skinner MW, Tortella B, Watson C, Winburn I, Members of the WFH Gene Therapy Registery Steering Committee. World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 2020 Jul; 26(4):563-564. PMID: 32462720; PMCID: PMC8944922.
      Citations: 11     Fields:    Translation:Humans
    71. Mahlangu JN. Requirements to participate in haemophilia clinical trials. Haemophilia. 2020 Apr; 26 Suppl 3:22-25. PMID: 32356347.
      Citations: 1     Fields:    Translation:Humans
    72. Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L, Winding B, Yuan H, Fruebis J, Rudin D, Oldenburg J. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502. PMID: 32227570; PMCID: PMC7384031.
      Citations: 23     Fields:    Translation:Humans
    73. Mahlangu J, Lopez Fernandez MF, Santagostino E, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Church N. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601. PMID: 32112434; PMCID: PMC7383510.
      Citations: 2     Fields:    Translation:Humans
    74. Pierce GF, Pasi KJ, Coffin D, Kaczmarek R, Lillicrap D, Mahlangu J, Rottellini D, Sannié T, Srivastava A, VandenDriessche T, Weill A, Members of the WFH Gene Therapy Round Table Program Organizing Committee. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 2020 May; 26(3):443-449. PMID: 32202382.
      Citations: 6     Fields:    Translation:Humans
    75. Peyvandi F, Lillicrap D, Mahlangu J, McLintock C, Pasi KJ, Pipe SW, Scales W, Srivastava A, VandenDriessche T. Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Res Pract Thromb Haemost. 2020 May; 4(4):644-651. PMID: 32548564; PMCID: PMC7292673.
      Citations: 6     
    76. Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138. PMID: 31697801; PMCID: PMC6908828.
      Citations: 102     Fields:    Translation:HumansCTClinical Trials
    77. Mahlangu J, Shikuku K, Dogara LG. Capacity building for inherited bleeding disorders in sub-Saharan Africa. Blood Adv. 2019 12 06; 3(Suppl 1):5-7. PMID: 31809543; PMCID: PMC7034125.
      Citations:    Fields:    Translation:HumansPHPublic Health
    78. Diop S, Haffar A, Mahlangu J, Chami I, Kitchen S, Pierce G. Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv. 2019 12 06; 3(Suppl 1):1-4. PMID: 31809546; PMCID: PMC7034121.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    79. Ely A, Bloom K, Maepa MB, Mahlangu JN, Pepper MS, Arbuthnot P. Gene and cell therapy in South Africa: Current status and future prospects. S Afr Med J. 2019 Sep 10; 109(8b):12-16. PMID: 31662143.
      Citations: 1     Fields:    Translation:HumansAnimals
    80. Mahlangu JN, Naidoo Y, Goga Y, Vaithlingum M, Joubert J, Sutton C, Potgieter J, Cruickshank AL, Iorio A. Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. S Afr Med J. 2019 Aug 28; 109(9):639-644. PMID: 31635587.
      Citations: 2     Fields:    Translation:Humans
    81. Thomson J, Hofmann A, Barrett CA, Beeton A, Bellairs GRM, Boretti L, Coetzee MJ, Farmer S, Gibbs MW, H Gombotz H, Hilton C, Kassianides C, Louw VJ, Lundgren C, Mahlangu JN, Noel CB, Rambiritch V, Schneider F, Verburgh E, Wessels PL, Wessels P, Wise R, Shander On Behalf Of The South African Patient Blood Management Group A. Patient blood management: A solution for South Africa. S Afr Med J. 2019 Jun 28; 109(7):471-476. PMID: 31266571.
      Citations: 8     Fields:    Translation:Humans
    82. Gupta N, Benbouzid A, Belhani M, El Andaloussi M, Maani K, Wali Y, Benchikh El Fegoun S, Saad HA, Mahlangu J. HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries. TH Open. 2019 Apr; 3(2):e190-e199. PMID: 31259302; PMCID: PMC6598083.
      Citations: 6     
    83. Mahlangu J. Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761. PMID: 31150297.
      Citations: 3     Fields:    Translation:Humans
    84. Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391. PMID: 31016855; PMCID: PMC6850115.
      Citations: 16     Fields:    Translation:Humans
    85. Louw S, Wan YO, Mayne ES, Mahlangu JN. Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing. Clin Lab. 2019 Apr 01; 65(4). PMID: 30969088.
      Citations:    Fields:    Translation:Humans
    86. Nalado AM, Mahlangu JN, Waziri B, Duarte R, Paget G, Olorunfemi G, Naicker S. Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa. Int J Nephrol Renovasc Dis. 2019; 12:19-32. PMID: 30858723; PMCID: PMC6385786.
      Citations: 8     
    87. Nalado AM, Dickens C, Dix-Peek T, Mahlangu JN, Olorunfemi G, Paget G, Duarte R, Naicker S. TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa. Int J Mol Epidemiol Genet. 2019; 10(1):1-9. PMID: 30911357; PMCID: PMC6420716.
      Citations: 2     
    88. Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220. PMID: 30724422.
      Citations: 16     Fields:    Translation:Humans
    89. Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50. PMID: 30536422.
      Citations: 7     Fields:    Translation:Humans
    90. Mahlangu J. rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943. PMID: 30449223.
      Citations: 3     Fields:    Translation:HumansAnimals
    91. Mahlangu JN. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570. PMID: 30430367.
      Citations: 5     Fields:    Translation:Humans
    92. Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44. PMID: 30427582.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    93. Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929. PMID: 30295389.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    94. Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol. 2018 Nov; 9(11):335-346. PMID: 30364483; PMCID: PMC6196631.
      Citations: 8     
    95. Nalado AM, Mahlangu JN, Duarte R, Paget G, Olorunfemi G, Jacobson BF, Naicker S. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899. PMID: 30281654; PMCID: PMC6169908.
      Citations: 7     Fields:    Translation:HumansCells
    96. Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920. PMID: 30248217.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    97. Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A, subcommittee on factor viii, factor ix and rare coagulation disorders. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018 10; 16(10):2106-2110. PMID: 30182468.
      Citations: 7     Fields:    Translation:Humans
    98. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822. PMID: 30157389.
      Citations: 196     Fields:    Translation:HumansCTClinical Trials
    99. Chowdary P, Angchaisuksiri P, Dimsits J, Iorio A, Kavakli K, Lentz SR, Mahlangu J, McCarthy A, Kessler C. Haemophilia clinical care and research needs: Assessing priorities. Haemophilia. 2018 07; 24(4):e270-e273. PMID: 30004622.
      Citations:    Fields:    Translation:Humans
    100. Mahlangu JN, Ahuja SP, Windyga J, Church N, Shah A, Schwartz L. BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review. Ther Adv Hematol. 2018 Jul; 9(7):191-205. PMID: 30013766; PMCID: PMC6041863.
      Citations: 1     
    101. Hermans C, Mahlangu J, Booth J, Schütz H, Santagostino E, Young G, Lee HY, Steinitz-Trost KN, Blanchette V, Berntorp E. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384. PMID: 29732708.
      Citations: 6     Fields:    Translation:Humans
    102. Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May; 24 Suppl 6:15-21. PMID: 29878661.
      Citations: 11     Fields:    Translation:Humans
    103. Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358. PMID: 29633467.
      Citations: 26     Fields:    Translation:HumansAnimals
    104. Oldenburg J, Kulkarni R, Srivastava A, Mahlangu JN, Blanchette VS, Tsao E, Winding B, Dumont J, Jain N. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84. PMID: 29082639.
      Citations: 17     Fields:    Translation:Humans
    105. Young JE, Grabell J, Tuttle A, Bowman M, Hopman WM, Good D, Rydz N, Mahlangu JN, James PD. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538. PMID: 28949433.
      Citations: 6     Fields:    Translation:Humans
    106. Hodkinson KE, Mahlangu JN. Deep-vein thrombosis in the era of high HIV and tuberculosis prevalence: A prospective review of its diagnosis and treatment in a quaternary centre. S Afr Med J. 2017 Sep 22; 107(10):859-863. PMID: 29022529.
      Citations: 4     Fields:    
    107. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818. PMID: 28691557.
      Citations: 312     Fields:    Translation:HumansCTClinical Trials
    108. Lentz SR, Rangarajan S, Karim FA, Andersen PD, Arkhammar P, Rosu G, Mahlangu J. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229. PMID: 27427786; PMCID: PMC5407628.
      Citations: 1     Fields:    Translation:Humans
    109. Shapiro AD, Mahlangu JN, Perry D, Pasi J, Quon DV, Chowdary P, Tsao E, Li S, Innes A, Pierce GF, Allen GA. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399. PMID: 28220631.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    110. Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, Diao L, Ramirez-Santiago A, Pierce GF, Allen G. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017 Feb; 4(2):e75-e82. PMID: 28159192.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    111. Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518. PMID: 28004057.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    112. James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P, Global Emerging HEmostasis Experts Panel (GEHEP). Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918. PMID: 27868369.
      Citations: 24     Fields:    Translation:Humans
    113. Mahlangu JN, Andreeva TA, Macfarlane DE, Walsh C, Key NS. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41. PMID: 27761964.
      Citations: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
    114. Mahlangu J, Paz P, Hardtke M, Aswad F, Schroeder J. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879. PMID: 27501279.
      Citations: 14     Fields:    Translation:Humans
    115. Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76. PMID: 27480487.
      Citations: 11     Fields:    Translation:Humans
    116. Wyrwich KW, Krishnan S, Auguste P, Poon JL, von Maltzahn R, Yu R, Pierce GF, Mei B, Mahlangu J, von Mackensen S. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872. PMID: 27385432.
      Citations: 20     Fields:    Translation:Humans
    117. Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30. PMID: 27405672.
      Citations: 14     Fields:    Translation:Humans
    118. Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66. PMID: 27333467.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    119. Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I, AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7. PMID: 27330001; PMCID: PMC4974198.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    120. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64. PMID: 27223147.
      Citations: 153     Fields:    Translation:Humans
    121. Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, Nogami K, Young G, Cristiano LM, Dong Y, Allen G, Pierce GF, Robinson B. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8. PMID: 26962852.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    122. Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76. PMID: 26970716.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    123. Prabdial-Sing N, Blackard JT, Puren AJ, Mahomed A, Abuelhassan W, Mahlangu J, Vermeulen M, Bowyer SM. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Antiviral Res. 2016 Mar; 127:90-8. PMID: 26704023.
      Citations: 4     Fields:    Translation:HumansCells
    124. Carcao M, Hilliard P, Escobar MA, Solimeno L, Mahlangu J, Santagostino E. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec; 95 Suppl 81:11-21. PMID: 26679393.
      Citations: 2     Fields:    Translation:Humans
    125. Schapkaitz E, Buldeo S, Mahlangu JN. Diagnosis of iron deficiency anaemia in hospital patients: Use of the reticulocyte haemoglobin content to differentiate iron deficiency anaemia from anaemia of chronic disease. S Afr Med J. 2015 Nov 20; 106(1):53-4. PMID: 26792306.
      Citations: 5     Fields:    Translation:HumansCells
    126. Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K, adept™2 Investigators. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98. PMID: 26362483.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    127. Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi KJ, Pabinger I, Jackson S, Cristiano LM, Li X, Pierce GF, Allen G. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80. PMID: 26218032.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    128. Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77. PMID: 25912075.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    129. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martín-Salces M, Angchaisuksiri P. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54. PMID: 25641556.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    130. Gillham A, Greyling B, Wessels TM, Mbele B, Schwyzer R, Krause A, Mahlangu J. Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86. PMID: 25828422.
      Citations: 6     Fields:    Translation:Humans
    131. Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A, Global Emerging Hemophilia Panel (GEHEP). Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97. PMID: 25689278.
      Citations: 16     Fields:    Translation:Humans
    132. Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800. PMID: 25196897.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    133. Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C, paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6. PMID: 25261199; PMCID: PMC4271178.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    134. Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34. PMID: 25208598.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    135. Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN, adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53. PMID: 24931322; PMCID: PMC4238784.
      Citations: 25     Fields:    Translation:Humans
    136. Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92. PMID: 24953131.
      Citations: 6     Fields:    Translation:Humans
    137. Blanchette VS, O'Mahony B, McJames L, Mahlangu JN. Assessment of outcomes. Haemophilia. 2014 May; 20 Suppl 4:114-20. PMID: 24762286.
      Citations: 3     Fields:    Translation:Humans
    138. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF, B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23. PMID: 24304002.
      Citations: 108     Fields:    Translation:HumansCTClinical Trials
    139. Gomez K, Klamroth R, Mahlangu J, Mancuso ME, Mingot ME, Ozelo MC. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29. PMID: 24333092; PMCID: PMC3934290.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    140. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF, A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25. PMID: 24227821; PMCID: PMC3894491.
      Citations: 159     Fields:    Translation:HumansCTClinical Trials
    141. James P, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Bidlingmaier C, Chitlur M, Fogarty P, Gomez K, Holm PA, Mahlangu J, Mancuso ME, Mingot-Castellano ME, Dolan G. Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfus Med Hemother. 2013 Oct; 40(5):352-5. PMID: 24273489; PMCID: PMC3822276.
      Citations: 2     
    142. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47. PMID: 22776238.
      Citations: 575     Fields:    Translation:Humans
    143. Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80. PMID: 22353395.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    144. de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A, 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9. PMID: 22470921.
      Citations: 9     Fields:    Translation:Humans
    145. Louw VJ, Bassa F, Chan SW, Dreosti L, Du Toit M, Ferreira M, Gartrell K, Gunther K, Jogessar V, Littleton N, Mahlangu J, McDonald A, Patel M, Pool R, Ruff P, Schmidt A, Sissolak G, Swart A, Verburgh E, Webb MJ. Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa. S Afr Med J. 2011 Nov 28; 101(12):900-6. PMID: 22273034.
      Citations:    Fields:    Translation:Humans
    146. Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP. Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8. PMID: 21649795; PMCID: PMC5319386.
      Citations: 5     Fields:    Translation:Humans
    147. Prabdial-Sing N, Giangaspero M, Puren AJ, Mahlangu J, Barrow P, Bowyer SM. Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa. J Virol Methods. 2011 Aug; 175(2):272-7. PMID: 21600241.
      Citations: 1     Fields:    Translation:HumansCells
    148. Mahlangu JN, Prabdial-Sing N. HCV genotypes of people with hemophilia in countries with high seroprevalances. Iran Red Crescent Med J. 2011 Feb; 13(2):142-3. PMID: 22737451; PMCID: PMC3371922.
      Citations:    
    149. Lawrie D, Coetzee LM, Becker P, Mahlangu J, Stevens W, Glencross DK. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009 Apr; 99(4):243-8. PMID: 19588777.
      Citations: 26     Fields:    Translation:Humans
    150. Prabdial-Sing N, Puren AJ, Mahlangu J, Barrow P, Bowyer SM. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58. PMID: 18946631.
      Citations: 6     Fields:    Translation:HumansCells
    151. Mahlangu JN, Medical and Scientific Council of the South African Haemophilia Foundation. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41. PMID: 18700842.
      Citations: 5     Fields:    Translation:Humans
    152. Zhang B, Spreafico M, Zheng C, Yang A, Platzer P, Callaghan MU, Avci Z, Ozbek N, Mahlangu J, Haw T, Kaufman RJ, Marchant K, Tuddenham EG, Seligsohn U, Peyvandi F, Ginsburg D. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600. PMID: 18391077; PMCID: PMC2424156.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    153. Mahlangu JN, Gilham A, Medical and Scientific Advisory Council of the South African Haemophilia Foundation. Guideline for the treatment of haemophilia in South Africa. S Afr Med J. 2008 Feb; 98(2 Pt 2):126-40. PMID: 18453313.
      Citations: 5     Fields:    Translation:Humans
    154. Mahlangu JN, Davids M. Three-way comparison of methods for the measurement of the erythrocyte sedimentation rate. J Clin Lab Anal. 2008; 22(5):346-52. PMID: 18803269; PMCID: PMC6649097.
      Citations: 12     Fields:    Translation:HumansCells
    155. Patel M, Mahlangu J, Patel J, Stevens G, Stevens W, Allard U, Mendelow B. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9. PMID: 11385317.
      Citations: 1     Fields:    Translation:HumansCells
    Mahlangu's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (311)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _